Why OmniAb, Inc.’s (OABI) Stock Is Down 5.92%
As of Thursday, October 08, OmniAb, Inc.’s OABI share price has dipped by 5.92%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company’s technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners’ drug development efforts. Its OmniAb platform’s Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics. The company offers animal-based technologies include OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences; OmniFlic, a bispecific rat and OmniClic, a bispecific chicken are designed for discovery of bispecific antibody applications; OmniTaur, which provides cow-inspired antibodies with unique structural characteristics for challenging targets; OmnidAb, an in vivo platform for the discovery of single-domain antibodies based upon a human VH scaffold; and OmniDeep, a suite of in silico, an artificial intelligence (AI) and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. It has an agreement with mAbsolve Ltd. for its Fc-silencing platform technology to incorporate the STR technology into antibodies that have been generated using OmniAb’s antibody discovery platform. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.
Commentary & Analysis
Why OmniAb, Inc.’s (OABI) Stock Is Up 8.24%
As of Wednesday, October 07, OmniAb, Inc.’s OABI share price has surged by 8.24%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why OmniAb, Inc.’s (OABI) Stock Is Down 7.42%
As of Tuesday, October 06, OmniAb, Inc.’s OABI share price has dipped by 7.42%, which has investors questioning if this is right time to buy.Jenna Brashear
Why OmniAb, Inc.’s (OABI) Stock Is Up 6.63%
As of Monday, September 14, OmniAb, Inc.’s OABI share price has surged by 6.63%, which has investors questioning if this is right time to sell.Jenna Brashear
Why OmniAb, Inc.’s (OABI) Stock Is Down 5.31%
As of Wednesday, September 09, OmniAb, Inc.’s OABI share price has dipped by 5.31%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | OABI | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $696.4 | $3,784.8 | 41% |
|
| Shares Out (Mil) | 128.8 | 106.1 | 67% |
|
| Institutional Ownership | 77.7% | 88.5% | 47% |
|
| Float (Mil) | 118.2 | 79.7 | 64% |
|
| Beta | 1.42 | 1.19 | 80% |
|
| Avg Daily Volume (000s) | 1,489 | 935 | 76% |
|
| Price Change (52-week) |
173.7% | 87.5% | 98% |
|
| Growth | OABI | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (4.3%) | 7.6% | 10% |
|
| Net Income (5yr) | (29.8%) | (8.4%) | 14% |
|
| EPS (5yr) | na | 3.2% | na |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (14.9%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 5 | 4 | |
| Current EPS | ($0.130) | ($0.366) | ($0.293) | |
| Month Ago EPS | ($0.130) | ($0.366) | ($0.295) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.118) | ($0.416) | ($0.323) | |
| Year/Year Chg | 188.9% | (35.8%) | (76.3%) | |
| Financials | OABI | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $39 | $800 | 18% |
|
| Net Income (TTM) (Mil) | ($44) | ($32) | 17% |
|
| EPS (TTM) | ($0.354) | ($0.300) | 30% |
|
| Operating Cash Flow (TTM) (Mil) | ($18) | $47 | 16% |
|
| Net Cash Flow (TTM) (Mil) | na | $3 | na |
|
| Long-Term Debt (Q1) (Mil) | $15 | $230 | 31% |
|
| Enterprise Value (Q1) (Mil) | $633 | $3,587 | 36% |
|
| Valuation | OABI | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.68 | 3.78 | 63% |
|
| P/E | na | 41.8 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 6.1 | na |
|
| Ratios | OABI | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 98.3% | 47.5% | 96% |
|
| Net Margin | (115.1%) | (6.0%) | 7% |
|
| ROA | (15.1%) | (4.8%) | 22% |
|
| ROE | (17.0%) | (7.9%) | 24% |
|
| Liabilities to Assets | 10.3% | 41.1% | 6% |
|
| F-Score | 5 | 5 | 50% |
|
Passing Stock Screens
As of 10/9/2026, from a list of 60 stock screening strategies,
GURU STRATEGY
Driehaus Screen
Factors: Size, Momentum, Growth, Earnings Estimates
Classic momentum approach that seeks out stocks that are rapidly rising in price with the belief that the rising price will attract other investors.
| Performance Since Inception: | 13.8% |
| +/- S&P 500: | +6.3 |
